Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2011-10-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.00277-10PMID 21968360PMCID PMC3256083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia

  2010cited by this paper
• Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.

  2008cited by this paper
• Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design.

  2008cited by this paper
• Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections

  2007cited by this paper
• Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections

  2007cited by this paper
• In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

  2000cited by this paper
• MINOCYCLINE EXCRETION AND DISTRIBUTION IN RELATION TO RENAL FUNCTION IN MAN

  1974influential reference

• Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development

  2026cites this paper
• Tigecycline pharmacodynamics in the hollow fiber system of Mycobacterium avium-complex lung disease, and the utility of MICs and time-kill studies in drug development

  2025cites this paper
• In vitro PK/PD modeling and simulation to accurately assess the antimicrobial activity of tigecycline against Mycobacterium abscessus

  2025cites this paper
• Tigecycline pharmacodynamics in the hollow fiber system of Mycobacterium avium-complex lung disease and the utility of MICs and time-kill studies in drug development

  2025cites this paper
• Serum concentration threshold and risk factors of tigecycline-induced hypofibrinogenaemia in critically ill patients.

  2024cites this paper
• In vitro antimicrobial activity of doxycycline, minocycline, and tigecycline against Mycobacterium abscessus complex: A meta-analysis study.

  2024cites this paper
• Synergistic Potential of Essential oils with Antibiotics for Antimicrobial Resistance with Emphasis on Mechanism of Action: A Review

  2024cites this paper
• Bacterial pathogens: Potential source for antimicrobial peptides.

  2023cites this paper
• Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation

  2023cites this paper
• Tigecycline Dosing Strategies in Critically Ill Liver-Impaired Patients

  2022cites this paper
• Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.

  2021cites this paper
• Dose optimization based on pharmacokinetic/pharmacodynamic target of tigecycline.

  2021cites this paper
• Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review

  2021cites this paper
• Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists

  2021cites this paper
• Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021

  2021cites this paper
• Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections

  2020cites this paper
• Safety and Efficacy of Tigecycline in ICU Patients Based on Therapeutic Drug Monitoring.

  2020cites this paper
• Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review.

  2020cites this paper
• Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis

  2020cites this paper
• Establishment and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Tigecycline in Critically Ill Patients

  2020cites this paper
• [Off label uses of tigecycline].

  2020cites this paper
• Population pharmacokinetics and exposure‐response analysis of tigecycline in patients with hospital‐acquired pneumonia

  2020cites this paper
• Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.

  2019cites this paper
• Once-a-week tigecycline for the treatment of drug-resistant TB.

  2019cites this paper
• The Role of Pharmacometrics in the Development of Antimicrobial Agents

  2018cites this paper
• Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

  2018cites this paper
• In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model

  2018cites this paper
• Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline

  2018cites this paper
• Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae

  2018cites this paper
• In vivo infection models in the pre‐clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents

  2017cites this paper
• In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model

  2017cites this paper
• Right Dose, Right Now: Customized Drug Dosing in the Critically Ill

  2017cites this paper
• Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae

  2017cites this paper
• Clinical pharmacokinetic–pharmacodynamic analyses: a critical element for developing antibacterial agents

  2017cites this paper
• Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?

  2017cites this paper
• In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model

  2017cites this paper
• Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.

  2016cites this paper
• Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease

  2016cites this paper
• Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.

  2016cites this paper
• Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections.

  2016cites this paper
• [Tigecycline: 10 years of history and still in full force].

  2015cites this paper
• Tigecycline: a critical safety review

  2015cites this paper
• Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

  2014cites this paper
• Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis.

  2014influential citation
• Bayesian approach to the design and analysis of non‐inferiority trials for anti‐infective products

  2014cites this paper
• Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012.

  2013cites this paper
• Tigecycline: an update.

  2013influential citation
• Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma

  2013cites this paper
• Efficacy of Tigecycline Alone and in Combination with Gentamicin in the Treatment of Experimental Endocarditis Due to Linezolid-Resistant Enterococcus faecium

  2013cites this paper